Background: Eribulin mesylate (ERI) is a microtubule dynamics inhibitor that has been demonstrated to prolong overall survival in metastatic breast cancer . Recently, ERI has shown to reduce the abnormality of the tumor microenvironment. Endocrine therapy has been reported to be ineffective under hypoxic conditions; however, improved oxygenation of the peritumoral area due to ERI may increase the sensitivity of endocrine therapy. Generally, the efficacy of endocrine therapy at late-line treatment is inferior to that of endocrine therapy at early-line. Hence, we hypothesized that endocrine therapy following ERI administration might be more effective.